Citations

Clear

1011 citation(s) found for "Barry, WT".

A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly
Ho, April J., Stein, Jason L. , Hua, Xue , Lee, Suh , Hibar, Derrek P., Leow, Alex , Dinov, Ivo D. , Toga, Arthur W. , Saykin, Andrew J. , Shen, Li , Pankratz, Nathan , Huentelman, Matthew J. , Craig, David W. , Gerber, Jill D., Allen, April N., Corneveaux, Jason J., Stephan, Dietrich A. , DeCarli, Charles , Dechairo, Bryan, Jack, Clifford R. , Weiner, Michael W. , Raji, Cyrus A. , Becker, James T. , Carmichael, Owen , Thompson, Paul M. , Initiative, the Alzheimer's Disease Neuroimaging, Thal, Leon J., Petersen, Ronald C., Jagust, William J. , Trojanowki, John Q., Toga, Arthur W., Gamst, Anthony, Potter, William Z., Montine, Tom, Anders, Dale, Felmlee, Joel P. , Schuff, Norbert, Alexander, Gene E. , Bandy, Dan, Foster, Norm, Reiman, Eric M. , Shaw, Les, Korecka, Magdalena , Toga, Arthur W., Crawford, Karen , Neu, Scott, Kornak, John , Kachaturian, Zaven, Frank, Richard , Molchan, Susan, Vorobik, Remi, Schneider, Lon S. , Pawluczyk, Sonia, Spann, Bryan , Fleisher, Adam , Vanderswag, Helen, Heidebrink, Judith L. , Johnson, Kris , Doody, Rachelle S., Villanueva‐Meyer, Javier , Chowdhury, Munir , Bell, Karen L. , Mintun, Mark A., Schneider, Stacy, Marson, Daniel , Griffith, Randall, Badger, Beverly, Grossman, Hillel, deToledo‐Morrell, Leyla, Bach, Julie , Duara, Ranjan , Isaacson, Richard , Strauman, Silvia, Albert, Marilyn S. , Pedroso, Julia, Toroney, Jaimie, Santi, Susan M De, Doraiswamy, P. Murali , Petrella, Jeffrey R. , Aiello, Marilyn, Clark, Christopher M. , Pham, Cassie, Nuñez, Jessica, Smith, Charles D., Given, Curtis A., Hardy, Peter , DeKosky, Steven T. , Oakley, MaryAnn, Simpson, Donna M., Ismail, M. Saleem , McCallum, Colleen, Cramer, Steven C. , Mulnard, Ruth A., Mc-Adams-Ortiz, Catherine, Martin-Cook, Kristen, Devous, Michael D. , Cellar, Janet S., Anderson, Heather S., Laubinger, Mary M., Bartzokis, George, Lu, Po H. , Fletcher, Rita, Parfitt, Francine, Farlow, Martin R. , Herring, Scott, Hake, Ann Marie , Dyck, Christopher H. van , MacAvoy, Martha G., Bifano, Laurel A., Chertkow, Howard, Bergman, Howard , Hosein, Chris, Graham, Simon J. , Caldwell, Curtis, Assaly, Michele, Hsiung, Ging‐Yuek Robin , Kertesz, Andrew , Trost, Dick, Bernick, Charles , Johnson, Nancy , Sadowsky, Carl, Villena, Teresa, Mesner, Scott, Aisen, Paul, Johnson, Kathleen, Behan, Kelly E., Johnson, Keith A. , Rosen, Allyson , Tinklenberg, Jared, Ashford, Wes, Connor, Donald J., Obradov, Sanja, Jayam‐Trouth, Annapurni , Wang, Paul J. , Auchus, Alexander P. , Huang, Juebin , DeCarli, Charles , Kittur, Smita, Mirje, Seema, Borrie, Michael, Lee, T‐Y, Asthana, Sanjay , Carlsson, Cynthia M., Highum, Diane, Preda, Adrian , Tariot, Pierre N. , Hendin, Barry , Kataki, Maria , Zimmerman, Earl A. , Celmins, Dzintra, Brown, Alice D., Gandy, Sam, Marenberg, Marjorie E., Rovner, Barry W. , Blank, Karen, Anderson, Karen, Santulli, Robert B. , Paré, Nadia, Williamson, Jeff D. , Raj, Balebail Ashok, Giordano, Amy T., Ott, Brian R. , Wu, Chuang‐Kuo, Cohen, Ronald A. , Wilks, Kerri, Lee, Ting‐Yim , Foroud, Tatiana , Potkin, Steven G. , López, Oscar L. , Initiative, the Alzheimer's Disease Neuroimaging, Toga, Arthur W., Beckett, Laurel , Green, Robert C. , Bernstein, Matt A. , Fox, Nick C. , Koeppe, Robert A. , Foster, Norm, Chen, Kewei , Lee, Virginia M.‐Y. , Toga, Arthur W., Harvey, Danielle , Snyder, Peter J. , Kaye, Jeffrey , Quinn, Joseph F. , Lord, Joanne L. , Stern, Yaakov , Honig, Lawrence S. , Morris, John C. , Tang, Cheuk Ying , Stern, Jessica A. , Shah, Raj C. , Duara, Ranjan , Rusinek, Henry , Leon, Mony J. de , Porsteinsson, Anton P. , Diaz‐Arrastia, Ramon , Levey, Allan I. , Lah, James J. , Burns, Jeffrey M. , Silverman, Daniel H.S. , Johnson, Heather K. , Black, Sandra E. , Feldman, Howard , ROGERS, John H. , Gitelman, Darren R. , Mesulam, Marsel M. , Sperling, Reisa Anne , Rentz, Dorene M. , Sabbagh, Marwan Noel , Killiany, Ronald , Norbash, Alexander , Obisesan, Thomas O. , Friedland, Robert P. , Fletcher, Evan M. , Johnson, Sterling C. , Nguyen, Dana R. , Scharre, Douglas W. , Beversdorf, David Q. , Gandy, Sam , Pearlson, Godfrey D. , Sink, Kaycee M. , Potter, Huntington , Jack, Clifford R , Saykin, Andrew J , Shen, Li , Preda, Adrian , Toga, Arthur W , Stein, Jason L , Thompson, Paul M , Hsiung, Gink-Yuek , Pankratz, Nathan

Mayo Clinic

Proceedings of the National Academy of Sciences | April 19, 2010 | Volume: 107 | Issue: 18 | Pages: 8404-8409

10.1073/pnas.0910878107 | PMID 20404173 Get It

A recently identified variant within the fat mass and obesity-associated ( FTO ) gene is carried by 46% of Western Europeans and is associated with an ~1.2 kg higher weight, on average, in adults and an ~1 cm greater waist circumference. With >1 billion overweight and 300 million obese persons worldwide, it is crucial to understand the implications of carrying this very common allele for the health of our aging population. FTO is highly expressed in the brain and elevated body mass index (BMI) is associated with brain atrophy, but it is unknown how the obesity-associated risk allele affects human brain structure. We therefore generated 3D maps of regional brain volume differences in 206 healthy elderly subjects scanned with MRI and genotyped as part of the Alzheimer's Disease Neuroimaging Initiative. We found a pattern of systematic brain volume deficits in carriers of the obesity-associated risk allele versus noncarriers. Relative to structure volumes in the mean template, FTO risk allele carriers versus noncarriers had an average brain volume difference of ~8% in the frontal lobes and 12% in the occipital lobes—these regions also showed significant volume deficits in subjects with higher BMI. These brain differences were not attributable to differences in cholesterol levels, hypertension, or the volume of white matter hyperintensities; which were not detectably higher in FTO risk allele carriers versus noncarriers. These brain maps reveal that a commonly carried susceptibility allele for obesity is associated with structural brain atrophy, with implications for the health of the elderly.
Survival and Immunogenicity of Mesenchymal Stem Cells From the Green Fluorescent Protein Transgenic Rat in the Adult Rat Brain
Moloney, Teresa C. , Dockery, Peter , Windebank, Anthony J. , Barry, Frank , Howard, Linda , Dowd, Eilís

Mayo Clinic

Neurorehabilitation and Neural Repair | April 8, 2010 | Volume: 24 | Issue: 7 | Pages: 645-656

10.1177/1545968309357745 | PMID 20378924 Get It

Background. A major technical limitation in preclinical cell replacement research is the ability to discriminate between donor and host tissue after transplantation. This problem has been lessened by the availability of transgenic animals that express “reporter” genes, such as green fluorescent protein (GFP). Objective. We determined the usefulness of one such transgenic reporter rat to assess the survival of bone marrow—derived rat mesenchymal stem cells (MSCs) following direct transplantation into the intact adult brain. We also sought to determine if the expression of GFP in the brain affected the survival of the MSCs or the host’s neuroimmune response to the cells. Methods. Rats received intrastriatal injections of sterile transplantation medium, 100 000 normal MSCs, or 100 000 GFP-MSCs and were killed humanely 1, 4, 7, 28, and 42 days posttransplantation for astrocyte and microglial immunohistochemical staining. Results. GFP-MSCs were evident at each examination, although their survival declined over time. Graft volume estimates comparing normal and GFP-MSCs revealed that GFP expression did not adversely affect the survival of the stem cells in the brain. Furthermore, immunostaining for astrocytes and microglia revealed that expression of the reporter protein did not affect the immunogenicity of the stem cells. Conclusions. These data indicate the usefulness of GFP for investigating the survival of MSCs following transplantation to the brain. However, the mechanisms responsible for the poor survival of the stem cells must be elucidated if these cells are to serve cell-based therapies for neurodegenerative disorders.
HCV Recurrence in HIV-Infected Patients After Liver Transplant
Hughes, Christopher B., Dickson, Rolland C. , Krishna, Murli , Willingham, Darrin L., Satyanarayana, Raj, Harnois, Denise M. , Rosser, Barry, Aranda‐Michel, Jaime, Kramer, David J., Hellinger, Walter C. , Mendez, Julio, Keaveny, Andrew P. , Rosser, Barry G.

Mayo Clinic

Journal of the International Association of Physicians in AIDS Care | March 31, 2010 | Volume: 9 | Issue: 2 | Pages: 87-93

10.1177/1545109710362592 | PMID 20357036 Get It

Patients coinfected with hepatitis C virus (HCV) and HIV undergoing liver transplantation (LT) are at risk of early, aggressive HCV recurrence. This study investigates the use of frequent protocol-driven biopsies to identify HCV recurrence post LT in coinfected patients. Five consecutive HIV/HCV-coinfected patients underwent LT. Liver biopsies were obtained post LT at 1 hour; days 7, 120, and 365; then annually; and as clinically indicated. Stage 2 (Ishak) or higher fibrosis occurred in 4 of the 5 patients by 60, 120, 270, and 365 days. Two patients died of HCV recurrence and liver failure at 6 and 35 months post LT. Three patients survived more than 4 years after LT, 2 having sustained virologic responses to anti-HCV treatment. Another has histologic recurrence not responding to treatment. Hepatitis C virus recurrence can be rapid and aggressive after LT in HIV-coinfected patients. Serial biopsies identify recurrence early, allowing for prompt initiation of treatment.
Targeting Adenoviruses with Factor X–Single-Chain Antibody Fusion Proteins
Chen, Christopher Y. , May, Shannon M., Barry, Michael A. , Barry, Michael A

Mayo Clinic

Human Gene Therapy | March 23, 2010 | Volume: 21 | Issue: 6 | Pages: 739-749

10.1089/hum.2009.190 | PMID 20331369 Get It

Size, Shape, and Stamina
Grewal, Jasmine , Ommen, Steve R. , Kane, Garvan C. , McCully, Robert B. , Pellikka, Patricia A. , Lam, Carolyn S.P. , Borlaug, Barry A. , Pellikka, Patricia A

Mayo Clinic

Hypertension | March 10, 2010 | Volume: 55 | Issue: 5 | Pages: 1143-1149

10.1161/hypertensionaha.109.146845 | PMID 20215563 Get It

Although several studies have examined the cardiac functional determinants of exercise capacity, few have investigated the effects of structural remodeling. The current study evaluated the association between cardiac geometry and exercise capacity. Subjects with ejection fraction ≥50% and no valvular disease, myocardial ischemia, or arrhythmias were identified from a large prospective exercise echocardiography database. Left ventricular mass index and relative wall thickness were used to classify geometry into normal, concentric remodeling, eccentric hypertrophy, and concentric hypertrophy. All of the subjects underwent symptom-limited treadmill exercise according to standard Bruce protocol. Maximal exercise tolerance was measured in metabolic equivalents. Of 366 (60±14 years; 57% male) subjects, 166 (45%) had normal geometry, 106 (29%) had concentric remodeling, 40 (11%) had eccentric hypertrophy, and 54 (15%) had concentric hypertrophy. Geometry was related to exercise capacity: in descending order, the maximum achieved metabolic equivalents were 9.9±2.8 in normal, 8.9±2.6 in concentric remodeling, 8.6±3.1 in eccentric hypertrophy, and 8.0±2.7 in concentric hypertrophy (all P <0.02 versus normal). Left ventricular mass index and relative wall thickness were negatively correlated with exercise tolerance in metabolic equivalents ( r =−0.14; P =0.009 and r =−0.21; P <0.001, respectively). Augmentation of heart rate and ejection fraction with exercise were blunted in concentric hypertrophy compared with normal, even after adjusting for medications. In conclusion, the pattern of ventricular remodeling is related to exercise capacity among low-risk adults. Subjects with concentric hypertrophy display the greatest limitation, and this is related to reduced systolic and chronotropic reserve. Reverse remodeling strategies may prevent or treat functional decline in patients with structural heart disease.
Clinical Predictors of a Diagnosis of Idiopathic Pulmonary Fibrosis
Fell, Charlene D. , Liu, Lyrica X., Murray, Susan , Han, MeiLan K., Kazerooni, Ella A. , Gross, Barry H., Colby, Thomas V. , Toews, Galen B., Flaherty, Kevin R. , Martínez, Fernando J. , Han, MeiLan King , Myers, Jeffrey L. , Travis, William D.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | January 7, 2010 | Volume: 181 | Issue: 8 | Pages: 832-837

10.1164/rccm.200906-0959oc | PMID 20056903 Get It

Abstract Rationale Idiopathic pulmonary fibrosis (IPF) and other idiopathic interstitial pneumonias (IIPs) have similar clinical and radiographic features, but their histopathology, response to therapy, and natural history differ. A surgical lung biopsy is often required to distinguish between these entities. Objectives We sought to determine if clinical variables could predict a histopathologic diagnosis of IPF in patients without honeycomb change on high-resolution computed tomography (HRCT). Methods Data from 97 patients with biopsy-proven IPF and 38 patients with other IIPs were examined. Logistic regression models were built to identify the clinical variables that predict histopathologic diagnosis of IPF. Measurements and Main Results Increasing age and average total HRCT interstitial score on HRCT scan of the chest may predict a biopsy confirmation of IPF. Sex, pulmonary function, presence of desaturation, or distance walked during a 6-minute walk test did not help discriminate pulmonary fibrosis from other IIPs. Conclusions Clinical data may be used to predict a diagnosis of IPF over other IIPs. Validation of these data with a prospective study is needed.
Caveat Medicus! Pulmonary Hypertension in the Elderly: A Word of Caution
Boilson, Barry A. , Schirger, John A., Borlaug, Barry A.

Mayo Clinic

European Journal of Heart Failure | December 18, 2009 | Volume: 12 | Issue: 1 | Pages: 89-93

10.1093/eurjhf/hfp171 | PMID 20023048 Get It

Abstract Heart failure with preserved ejection fraction (HFpEF) is a common but under-recognized cause of pulmonary hypertension (PH), particularly among the elderly. While elevated pulmonary artery pressures are clearly associated with increased mortality in HFpEF, it remains unknown whether or how pulmonary vascular disease in HFpEF should be treated. This case emphasizes the importance of maintaining a high index of suspicion for HFpEF in elderly patients presenting with PH and illustrates potential hazards associated with selective pulmonary vasodilation in this growing population.
Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines
Nehete, Pramod N. , Nehete, Bharti P. , Buchl, Stephanie J., Palmer, Donna , Montefiori, David C. , Ng, Philip , Sastry, K. Jagannadha , Barry, Michael A. , Weaver, Eric A. , Weaver, Eric A , Barry, Michael A

Mayo Clinic

Viruses | November 10, 2009 | Volume: 1 | Issue: 3 | Pages: 920-938

10.3390/v1030920 | PMID 20107521 Get It

Groups of rhesus macaques that had previously been immunized with HIV-1 envelope (env) peptides and first generation adenovirus serotype 5 (FG-Ad5) vaccines expressing the same peptides were immunized intramuscularly three times with helperdependent adenovirus (HD-Ad) vaccines expressing only the HIV-1 envelope from JRFL. No gag, pol, or other SHIV genes were used for vaccination. One group of the FG-Ad5-immune animals was immunized three times with HD-Ad5 expressing env. One group was immunized by serotype-switching with HD-Ad6, HD-Ad1, and HD-Ad2 expressing env. Previous work demonstrated that serum antibody levels against env were significantly higher in the serotype-switched group than in the HD-Ad5 group. In this study, neutralizing antibody and T cell responses were compared between the groups before and after rectal challenge with CCR5-tropic SHIV-SF162P3. When serum samples were assayed for neutralizing antibodies, only weak activity was observed. T cell responses against env epitopes were higher in the serotype-switched group. When these animals were challenged rectally with SHIV-SF162P3, both the Ad5 and serotype-switch groups significantly reduced peak viral loads 2 to 10-fold 2 weeks after infection. Peak viral loads were significantly lower for the serotype-switched group as compared to the HD-Ad5-immunized group. Viral loads declined over 18 weeks after infection with some animals viremia reducing nearly 4 logs from the peak. These data demonstrate significant mucosal vaccine effects after immunization with only env antigens. These data also demonstrate HD-Ad vectors are a robust platform for vaccination.
Vascular metallomics: Copper in the vasculature
Easter, Renee N., Chan, Qilin , Ritman, Erik L., Caruso, Joseph A. , Qin, Zhenyu , Lai, Barry Chi Hong

Mayo Clinic

Vascular Medicine | October 6, 2009 | Volume: 15 | Issue: 1 | Pages: 61-69

10.1177/1358863x09346656 | PMID 19808712 Get It

Owing to recent progress in analytical techniques, metallomics are evolving from detecting distinct trace metals in a defined state to monitor the dynamic changes in the abundance and location of trace metals in vitro and in vivo. Vascular metallomics is an emerging field that studies the role of trace metals in vasculature. This review will introduce common metallomics techniques including atomic absorption spectrometry, inductively coupled plasma-atomic emission spectrometry, inductively coupled plasma-mass spectrometry and X-ray fluorescence spectrometry with a summary table to compare these techniques. Moreover, we will summarize recent research findings that have applied these techniques to human population studies in cardiovascular diseases, with a particular emphasis on the role of copper in these diseases. In order to address the issue of interdisciplinary studies between metallomics and vascular biology, we will review the progress of efforts to understand the role of copper in neovascularization. This recent advance in the metallomics field may be a powerful tool to elucidate the signaling pathways and specific biological functions of these trace metals. Finally, we summarize the evidence to support the notion that copper is a dynamic signaling molecule. As a future direction, vascular metallomics studies may lead to the identification of targets for diagnosis and therapy in cardiovascular disease.
Infection and Killing of Multiple Myeloma by Adenoviruses
Senac, Julien S., Doronin, Konstantin, Russell, Stephen J. , Jelinek, Diane F., Greipp, Philip R., Barry, Michael A. , Russell, Stephen J , Barry, Michael A

Mayo Clinic

Human Gene Therapy | September 29, 2009 | Volume: 21 | Issue: 2 | Pages: 179-190

10.1089/hum.2009.082 | PMID 19788385 Get It

Oncolytic virotherapy makes use of the natural ability of viruses to infect and kill cancer cells. Adenovirus serotype 5 (Ad5) has been approved for use in humans as a therapy for solid cancers. In this study, we have tested whether Ad5 and low-seroprevalence adenoviruses can be used as oncolytics for multiple myeloma (MM). We show that Ad5 productively infects most myeloma cell lines, replicates to various degrees, and mediates oncolytic cell killing in vitro and in vivo. Comparison of Ad5 with low-seroprevalence Ads on primary marrow samples from MM patients revealed striking differences in the abilities of different adenoviral serotypes to kill normal CD138 – cells and CD138 + MM cells. Ad5 and Ad6 from species C and Ad26 and Ad48 from species D all mediated killing of CD138 + cells with low-level killing of CD138 – cells. In contrast, Ad11, Ad35, Ad40, and Ad41 mediated weak oncolytic effects in all of the cells. Comparison of cell binding, cell entry, and replication revealed that Ad11 and Ad35 bound MM cells 10 to 100 times better than other serotypes. However, after this efficient interaction, Ad11 and Ad35 viral DNA was not replicated and cell killing did not occur. In contrast, Ad5, Ad6, Ad26, and Ad48 all replicated 10- to 100-fold in MM cells and this correlated with cell killing. These data suggest that Ad5 and other low-seroprevalence adenoviruses may have utility as oncolytic agents against MM and other hematologic malignancies.